2026· [Rinsho ketsueki] The Japanese journal of clinical hematology· Vol 67 7, pp.
802-810
· 0 citations
Medicine
TL;DR
The use of venetoclax-based regimens, FLT3 inhibitors, and IDH inhibitors has improved treatment outcomes by enabling the achievement of measurable residual disease (MRD)-negative remission, highlighting the importance of maintenance strategies using azacitidine and FLT3 inhibitors, as well as MRD-guided preemptive interventions.
A review of the current concepts of post-transplant maintenance therapy in AML/MDS discusses emerging evidence supporting MRD-guided treatment strategies and molecularly targeted maintenance approaches, highlighting future perspectives for optimizing relapse prevention after allo-HSCT.
Y. Najima· [Rinsho ketsueki] The Japane...· 0 citations
PURPOSE OF REVIEW
Relapse remains the leading cause of treatment failure after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and outcomes after relapse are poor. This review summarizes and critically appraises current evidence for post-HCT main...
Nihar Desai, I. Pašić· Current opinion in hematolog...· 1 citation
This review synthesizes contemporary breakthroughs in HSCT biology, technology, and clinical application, critically examines unresolved barriers, and highlights future directions, including Artificial Intelligence (AI)-driven predictive analytics, universal donor platforms, and equitable global access strategies.
M. Abah, Ovwigho Ugbede, Oghenetejiri C et al.· DS Reviews of Research in Li...· 0 citations
To the Editor: Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains one of the most challenging events in adult acute lymphoblastic leukemia (ALL) and a leading cause of treatment failure [1, 2]. Second allo-HCT has historically been regarded as the only potentially curative option for patient...
Jaehyun Ahn, Daehun Kwag, G. Min et al.· Blood Cancer Journal· 0 citations
